Merck and Moderna outline next steps for mRNA cancer vaccine
Executives from Merck and Moderna said they still have significant work to do after an early cancer vaccine success. At the STAT Summit, Stephen Hoge and Dean Li explained how the companies plan to combine Keytruda with personalized mRNA vaccines to target tumors.
The two companies are Merck and Moderna. Their executives, Stephen Hoge and Dean Li, used the STAT Summit to describe what comes next. They said an early win in cancer vaccine research does not mean the job is finished. Their proposed strategy pairs Keytruda with personalized mRNA vaccines designed to go after tumors. This places the effort within the broader field of cancer research, where mRNA technology and existing treatments are being studied together.
If further work supports the approach, cancer patients could gain another possible treatment option, though much remains uncertain. Researchers and clinicians may need to assess how personalized mRNA vaccines fit alongside existing drugs. Merck and Moderna could face pressure to show that the strategy works broadly. For now, the early result may shape expectations more than practice, so its societal impact is likely to depend on later evidence.